David E. Onions, PhD Norcliffe Capital

David Onions is a consultant to and investor in biomedical companies. He was a founder member of 2 biotechnology companies (Q-One Biotech and BioOutsource) which, in total, exited for ˜$100M. He became CMO of Invitrogen Life Technologies and was involved in the buy-out of BioReliance where he was CSO and Board Director. The company was subsequently sold to Sigma-Aldrich (now Merck KGaA). Formerly, David was Director of the Leukaemia Research Fund’s Virus Centre and Professor of Veterinary Virology at the University of Glasgow. He has been awarded the Norman Hall Gold Medal for Research into Animal Diseases from the Royal College of Veterinary Surgeons, the Animal Health Trust Award for Outstanding Scientific Achievement and The British Veterinary Association’s Cup and Medal for contributions to veterinary science. In 2006 he received an Honorary Doctorate from the University of Glasgow for services to biotechnology and veterinary medicine.

David Onions is a member, or former member, of several advisory groups including the UK Advisory Committee on Release of GMOs Into the Environment the FDA xenotransplantation advisory committee, The World Health Organisations Expert Advisory Panel on Biological Standardization and The UK Medical Research Council Stem Foundation.